Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 7 |
NetGPI | no | yes: 0, no: 7 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005681 | spliceosomal complex | 3 | 1 |
GO:0005737 | cytoplasm | 2 | 1 |
GO:0031974 | membrane-enclosed lumen | 2 | 1 |
GO:0031981 | nuclear lumen | 5 | 1 |
GO:0032838 | plasma membrane bounded cell projection cytoplasm | 4 | 1 |
GO:0032991 | protein-containing complex | 1 | 1 |
GO:0043233 | organelle lumen | 3 | 1 |
GO:0070013 | intracellular organelle lumen | 4 | 1 |
GO:0071013 | catalytic step 2 spliceosome | 3 | 1 |
GO:0097014 | ciliary plasm | 5 | 1 |
GO:0099568 | cytoplasmic region | 3 | 1 |
GO:0110165 | cellular anatomical entity | 1 | 2 |
GO:0140513 | nuclear protein-containing complex | 2 | 1 |
GO:1902494 | catalytic complex | 2 | 1 |
GO:1990904 | ribonucleoprotein complex | 2 | 1 |
GO:0016020 | membrane | 2 | 1 |
Related structures:
AlphaFold database: A4HN31
Term | Name | Level | Count |
---|---|---|---|
GO:0000413 | protein peptidyl-prolyl isomerization | 7 | 8 |
GO:0006807 | nitrogen compound metabolic process | 2 | 8 |
GO:0008152 | metabolic process | 1 | 8 |
GO:0018193 | peptidyl-amino acid modification | 5 | 8 |
GO:0018208 | peptidyl-proline modification | 6 | 8 |
GO:0019538 | protein metabolic process | 3 | 8 |
GO:0036211 | protein modification process | 4 | 8 |
GO:0043170 | macromolecule metabolic process | 3 | 8 |
GO:0043412 | macromolecule modification | 4 | 8 |
GO:0044238 | primary metabolic process | 2 | 8 |
GO:0071704 | organic substance metabolic process | 2 | 8 |
GO:1901564 | organonitrogen compound metabolic process | 3 | 8 |
GO:0006457 | protein folding | 2 | 1 |
GO:0009987 | cellular process | 1 | 1 |
Term | Name | Level | Count |
---|---|---|---|
GO:0003755 | peptidyl-prolyl cis-trans isomerase activity | 3 | 8 |
GO:0003824 | catalytic activity | 1 | 8 |
GO:0016853 | isomerase activity | 2 | 8 |
GO:0016859 | cis-trans isomerase activity | 3 | 8 |
GO:0140096 | catalytic activity, acting on a protein | 2 | 8 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 153 | 157 | PF00656 | 0.325 |
CLV_PCSK_SKI1_1 | 197 | 201 | PF00082 | 0.192 |
DEG_APCC_DBOX_1 | 57 | 65 | PF00400 | 0.399 |
DEG_Nend_UBRbox_2 | 1 | 3 | PF02207 | 0.412 |
DOC_CDC14_PxL_1 | 139 | 147 | PF14671 | 0.192 |
DOC_CYCLIN_yCln2_LP_2 | 20 | 26 | PF00134 | 0.420 |
DOC_MAPK_FxFP_2 | 24 | 27 | PF00069 | 0.417 |
DOC_MAPK_gen_1 | 68 | 77 | PF00069 | 0.312 |
DOC_MAPK_MEF2A_6 | 116 | 123 | PF00069 | 0.349 |
DOC_MAPK_MEF2A_6 | 133 | 142 | PF00069 | 0.164 |
DOC_MAPK_MEF2A_6 | 16 | 24 | PF00069 | 0.412 |
DOC_MAPK_MEF2A_6 | 58 | 65 | PF00069 | 0.481 |
DOC_MAPK_MEF2A_6 | 68 | 77 | PF00069 | 0.283 |
DOC_MAPK_NFAT4_5 | 58 | 66 | PF00069 | 0.397 |
DOC_PP2B_LxvP_1 | 20 | 23 | PF13499 | 0.419 |
DOC_PP4_FxxP_1 | 24 | 27 | PF00568 | 0.490 |
DOC_PP4_FxxP_1 | 32 | 35 | PF00568 | 0.502 |
DOC_USP7_MATH_1 | 149 | 153 | PF00917 | 0.312 |
DOC_USP7_MATH_1 | 214 | 218 | PF00917 | 0.332 |
DOC_USP7_MATH_1 | 94 | 98 | PF00917 | 0.427 |
DOC_USP7_UBL2_3 | 287 | 291 | PF12436 | 0.469 |
DOC_WW_Pin1_4 | 210 | 215 | PF00397 | 0.280 |
LIG_14-3-3_CanoR_1 | 189 | 195 | PF00244 | 0.332 |
LIG_14-3-3_CanoR_1 | 299 | 309 | PF00244 | 0.298 |
LIG_14-3-3_CanoR_1 | 58 | 64 | PF00244 | 0.399 |
LIG_APCC_ABBAyCdc20_2 | 291 | 297 | PF00400 | 0.312 |
LIG_BRCT_BRCA1_1 | 205 | 209 | PF00533 | 0.273 |
LIG_BRCT_BRCA1_1 | 61 | 65 | PF00533 | 0.392 |
LIG_BRCT_BRCA1_1 | 96 | 100 | PF00533 | 0.349 |
LIG_EH_1 | 309 | 313 | PF12763 | 0.433 |
LIG_eIF4E_1 | 33 | 39 | PF01652 | 0.391 |
LIG_FHA_1 | 15 | 21 | PF00498 | 0.406 |
LIG_FHA_1 | 70 | 76 | PF00498 | 0.465 |
LIG_FHA_1 | 90 | 96 | PF00498 | 0.354 |
LIG_FHA_2 | 247 | 253 | PF00498 | 0.556 |
LIG_FHA_2 | 78 | 84 | PF00498 | 0.332 |
LIG_LIR_Gen_1 | 136 | 146 | PF02991 | 0.332 |
LIG_LIR_Gen_1 | 219 | 230 | PF02991 | 0.332 |
LIG_LIR_Gen_1 | 97 | 108 | PF02991 | 0.349 |
LIG_LIR_Nem_3 | 113 | 118 | PF02991 | 0.337 |
LIG_LIR_Nem_3 | 136 | 142 | PF02991 | 0.332 |
LIG_LIR_Nem_3 | 217 | 221 | PF02991 | 0.367 |
LIG_LIR_Nem_3 | 223 | 228 | PF02991 | 0.373 |
LIG_LIR_Nem_3 | 306 | 312 | PF02991 | 0.421 |
LIG_LIR_Nem_3 | 5 | 9 | PF02991 | 0.391 |
LIG_LIR_Nem_3 | 97 | 103 | PF02991 | 0.396 |
LIG_LYPXL_yS_3 | 118 | 121 | PF13949 | 0.192 |
LIG_MLH1_MIPbox_1 | 205 | 209 | PF16413 | 0.273 |
LIG_SH2_SRC | 33 | 36 | PF00017 | 0.402 |
LIG_SH2_STAT5 | 175 | 178 | PF00017 | 0.332 |
LIG_SH2_STAT5 | 222 | 225 | PF00017 | 0.337 |
LIG_SH2_STAT5 | 33 | 36 | PF00017 | 0.402 |
LIG_SH2_STAT5 | 6 | 9 | PF00017 | 0.393 |
LIG_SH3_3 | 137 | 143 | PF00018 | 0.192 |
LIG_SUMO_SIM_anti_2 | 59 | 65 | PF11976 | 0.395 |
LIG_WRC_WIRS_1 | 95 | 100 | PF05994 | 0.349 |
MOD_CK1_1 | 59 | 65 | PF00069 | 0.427 |
MOD_CK2_1 | 232 | 238 | PF00069 | 0.509 |
MOD_CK2_1 | 246 | 252 | PF00069 | 0.626 |
MOD_GlcNHglycan | 105 | 108 | PF01048 | 0.296 |
MOD_GlcNHglycan | 234 | 237 | PF01048 | 0.478 |
MOD_GlcNHglycan | 257 | 260 | PF01048 | 0.640 |
MOD_GlcNHglycan | 284 | 287 | PF01048 | 0.474 |
MOD_GlcNHglycan | 303 | 306 | PF01048 | 0.273 |
MOD_GSK3_1 | 122 | 129 | PF00069 | 0.307 |
MOD_GSK3_1 | 210 | 217 | PF00069 | 0.374 |
MOD_N-GLC_1 | 203 | 208 | PF02516 | 0.276 |
MOD_N-GLC_1 | 246 | 251 | PF02516 | 0.592 |
MOD_N-GLC_1 | 255 | 260 | PF02516 | 0.582 |
MOD_N-GLC_1 | 59 | 64 | PF02516 | 0.396 |
MOD_NEK2_1 | 103 | 108 | PF00069 | 0.332 |
MOD_NEK2_1 | 14 | 19 | PF00069 | 0.445 |
MOD_NEK2_1 | 181 | 186 | PF00069 | 0.344 |
MOD_NEK2_1 | 208 | 213 | PF00069 | 0.275 |
MOD_NEK2_1 | 77 | 82 | PF00069 | 0.284 |
MOD_NEK2_2 | 134 | 139 | PF00069 | 0.273 |
MOD_PIKK_1 | 203 | 209 | PF00454 | 0.298 |
MOD_PKA_2 | 188 | 194 | PF00069 | 0.397 |
MOD_Plk_1 | 203 | 209 | PF00069 | 0.332 |
MOD_Plk_1 | 255 | 261 | PF00069 | 0.614 |
MOD_Plk_1 | 59 | 65 | PF00069 | 0.395 |
MOD_Plk_2-3 | 156 | 162 | PF00069 | 0.192 |
MOD_Plk_4 | 110 | 116 | PF00069 | 0.337 |
MOD_Plk_4 | 134 | 140 | PF00069 | 0.273 |
MOD_Plk_4 | 2 | 8 | PF00069 | 0.395 |
MOD_Plk_4 | 303 | 309 | PF00069 | 0.442 |
MOD_Plk_4 | 59 | 65 | PF00069 | 0.395 |
MOD_ProDKin_1 | 210 | 216 | PF00069 | 0.280 |
MOD_SUMO_rev_2 | 285 | 293 | PF00179 | 0.454 |
TRG_DiLeu_BaLyEn_6 | 34 | 39 | PF01217 | 0.388 |
TRG_DiLeu_BaLyEn_6 | 51 | 56 | PF01217 | 0.380 |
TRG_ENDOCYTIC_2 | 118 | 121 | PF00928 | 0.336 |
TRG_ENDOCYTIC_2 | 222 | 225 | PF00928 | 0.371 |
TRG_ENDOCYTIC_2 | 309 | 312 | PF00928 | 0.419 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1HUZ6 | Leptomonas seymouri | 63% | 100% |
A0A0S4J2C4 | Bodo saltans | 29% | 69% |
A0A3Q8IPW3 | Leishmania donovani | 81% | 100% |
A4IBQ0 | Leishmania infantum | 81% | 100% |
E9AFI5 | Leishmania major | 83% | 100% |
E9B6P0 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 82% | 100% |
P0C1I1 | Rhizopus delemar (strain RA 99-880 / ATCC MYA-4621 / FGSC 9543 / NRRL 43880) | 27% | 88% |